VB 2011

Drug Profile

VB 2011

Alternative Names: H-11; H-11 scFv; Novomab-G2 scFv; VB2-011

Latest Information Update: 12 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viventia Biotech
  • Developer University of Alabama at Birmingham
  • Class Antibody diagnostics; Antineoplastics; Immunoglobulin Fv fragments
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Oct 2000 Novopharm Biotech is now called Viventia Biotech
  • 19 Sep 2000 Preclinical development for Breast cancer in Canada (IV)
  • 01 Dec 1999 A study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top